Thomas M. Sobol, Hagens Berman Sobol Shapiro executive committee member and managing partner of the firm’s Boston office, was recently named a 2026 Competition/Antitrust MVP by Law360, recognized for a year of landmark results, including a jury verdict that exceeds $2.4 billion after trebling, the largest known intact jury verdict under the Sherman Act.
Tom Sobol’s Biggest 2026 Wins in Antitrust Litigation
In 2026, Tom secured results worth well over $2 billion against major drugmakers, adding to a career defined by record-setting outcomes in antitrust and drug-pricing litigation.
Amitiza $2.4 Billion Pay-for-Delay Verdict: Largest Intact Sherman Act Jury Award
In re Amitiza Antitrust Litigation, No. 1:21-cv-11057-MJJ (D. Mass.)
As lead trial counsel, Tom directed the trial team and trial strategy in this case against Takeda. On May 18, 2026, the jury returned a first-of-its-kind verdict of $474.89 million for the direct purchaser class plaintiffs, $346.8 million for the retailer plaintiffs and $63.2 million for the end payor class plaintiffs. After automatic trebling of the federal antitrust claims, the total direct purchaser award exceeds $2.4 billion – the largest intact jury verdict under the Sherman Act. This also marked the first plaintiffs’ verdict in an antitrust case alleging the brand-name drugmaker paid a generic competitor to delay launching a less expensive version of its drug, otherwise known as a reverse payment or pay-for-delay.
Tom was joined on the trial team by Hagens Berman attorneys Kristen A. Johnson, Erin C. Burns, Jessica R. MacAuley, Laura Hayes, Rebekah Glickman-Simon, Daniel Polonsky, Whitney Street, and trial paralegals Valeria Alvarez and Riya Jha, as well as co-counsel firms Roberts Law Firm US, PC; Sperling & Slater, P.C.; and Radice Law Firm, P.C.
Read more about the Amitiza antitrust case »
Tracleer Antitrust Litigation: $65 Million Settlement
Government Employees Health Association v. Actelion Pharmaceuticals Ltd., et al., No. 1:18-cv-03560-GLR (D. Md.)
Tom served as co-lead counsel for a certified class of third-party payors in this class-action lawsuit alleging that defendants engaged in a scheme to prolong their monopoly over bosentan, a drug sold under the brand name Tracleer at an average cost of approximately $100,000 per patient per year. On July 1, 2026, Chief U.S. District Judge George L. Russell III issued an order approving the $65 million settlement.
Tom was joined on the litigation team by Hagens Berman attorneys Erin C. Burns, Kristen A. Johnson, and Rachel Downey and paralegal Valeria Alvarez, as well as co-lead counsel firms Radice Law Firm, P.C; the Law Offices of E. David Hiskins, LLC and Rawlings & Associates, PLLC.
Read more about the Tracleer antitrust settlement »
Stelara Antitrust Litigation: First-Ever Class Certification in a Case Alleging Delayed Biosimilar Competition
CareFirst of Maryland, Inc., et al. v. Johnson & Johnson, et al., No. 2:23-cv-00629-JKW-LRL (E.D. Va.)
Tom developed the theory of liability underlying this novel case against Johnson & Johnson, which alleges patent misuse and delayed biosimilar competition. With his partner Hannah Brennan serving as co-lead counsel for the class of end payors, Tom helped lead the team in certifying the class — the first class ever certified in a case alleging delayed biosimilar competition.
Other members of the litigation team include Hannah Brennan (appointed interim co-lead class counsel), Whitney Street, Rebekah Glickman-Simon, Michael H. Lavine and paralegal Chavay Williams, along with co-lead counsel at Lowey Dannenberg, P.C.
Read more about the Stelara antitrust case »
Lantus Insulin Antitrust Litigation: Summary Judgment Win Against Sanofi
In re Lantus Direct Purchaser Antitrust Litigation, No. 1:16-cv-12652-LTS (D. Mass.)
Tom originated this novel case challenging the soaring cost of insulin in the United States. Plaintiffs allege that Sanofi submitted patents for listing in the FDA’s “Orange Book” that did not meet the legal standard for doing so, giving Sanofi the power to delay competitors from entering the market by up to two and a half years.
On March 24, 2026, U.S. District Judge Leo T. Sorokin issued an order on summary judgment, adopting the report and recommendation of Chief Magistrate Judge Jennifer Boal. The court agreed with plaintiffs that Sanofi improperly submitted the Lantus SoloStar device patents and denied Sanofi’s motion for summary judgment in its entirety. Trial was set to begin Jan. 11, 2027. In November 2026, the case settled on confidential terms. Members of the litigation team include Kristen A. Johnson, Michael H. Lavine, Rachel Downey, Henry Huttinger, Jessica R. MacAuley and Rebekah Glickman-Simon, as well as paralegals Valeria Alvarez and Annetta Giannetto.
Read more about the Lantus insulin antitrust case »
About Tom’s Career Wins in Drug Pricing Litigation
Tom leads the firm’s Boston office, which has secured record-breaking settlements in pharmaceutical and medical device-related class actions. Over his career, he has helped achieve wins totaling more than $6.5 billion for consumers, health plans and purchasers. He has been honored by the American Antitrust Institute for Outstanding Antitrust Litigation Achievement and was named a Trial Lawyer of the Year finalist by Public Justice.
